Coexisting end stage liver disease (ESLD) and end stage renal disease (ESRD) for a patient on dialysis is a standard indication for a combined liver-kidney transplantation (CLKT). A survival advantage after CLKT has been verified in liver transplant candidates with significant kidney dysfunction due to chronic kidney disease (CKD) or acute kidney injury (AKI). The severity (glomerular filtration rate (GFR) ≤30 mL/min) and duration (more than 8~12 weeks) of kidney dysfunction are strong determinants for the selection of CLKT candidates. The CLKT patient survival rate is superior to that of liver transplant alone in candidates with a serum creatinine ＞2.0 mg/dL or who are on dialysis. Because of the immunological modulation effect of the liver graft, post-transplant CLTX results in a lower incidence of acute rejection and higher long-term censored graft survival rate in kidney transplant recipients. Despite the advantages of CLKT, the CLKT waiting list is extremely rare in Korea (0.80%, 67/3,717, from recent Korean Network for Organ Sharing (KONOS) data on March 2010). The narrow indications for CLKT (only ESRD candidates on dialysis are accepted for CLKT) and inferior ranking of CLKT for kidney allocation is a pitfall of the multi-organ allocation rule in KONOS.
. Kidney indication for combined liver-kidney transplantation
Kidney diseases Criteria
End-stage renal disease on renal replacement treatment Chronic renal disease GFR ≤30 mL/min GFR ＜20 mL/min + duration ≥12 weeks Renal biopsy proven glomerulosclerosis ＞30% or fibrosis ＞30% Acute kidney injury Serum creatinine ≥ 2.0 mg/dL + dialysis duration ≥8 weeks Abbreviation: GFR, glomerular filtration rate. 
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